Interleukin 11 May improve thrombocytopenia associated with Imatinib mesylate therapy in chronic Myelogenous leukemia

Patricia Ault, Hagop Kantarjian, Mary Alma Welch, Francis Giles, Mary Beth Rios, Jorge Cortes

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

During therapy with imatinib (Gleevec), 20-30% of patients with CML in chronic phase develop grade≥3 thrombocytopenia. This leads to treatment interruptions and dose reductions that result in a decreased probability of achieving a cytogenetic response. Interleukin-11 (oprelvekin) is a megakaryopoietic cytokine that reduces the incidence and severity of thrombocytopenia associated with chemotherapy. We report on the use of interleukin-11 in three CML patients with grade≥3, imatinib-induced thrombocytopenia. In all three patients, interleukin-11 led to improved platelets, uninterrupted administration of imatinib and improved cytogenetic response. This observation suggests that interleukin-11 may be beneficial for patients with imatinib-induced thrombocytoepnia.

Original languageEnglish (US)
Pages (from-to)613-618
Number of pages6
JournalLeukemia Research
Volume28
Issue number6
DOIs
StatePublished - Jun 1 2004
Externally publishedYes

    Fingerprint

Keywords

  • CBC
  • Chronic myelogenous leukemia
  • Chronic myeloid leukemia
  • CML
  • Complete blood cell count
  • G-CSG
  • Granulocyte colony stimulating factor (Filgrastin)
  • IL-11
  • Imatinib
  • Interleukin-11
  • Oprelvekin
  • Thrombocytopenia
  • WBC
  • White blood cell count

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this